請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51592完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳祈安(Chi-An CHEN),鄭文芳(Wen-Fang CHENG) | |
| dc.contributor.author | Ying-Cheng CHIANG | en |
| dc.contributor.author | 江盈澄 | zh_TW |
| dc.date.accessioned | 2021-06-15T13:40:17Z | - |
| dc.date.available | 2016-02-24 | |
| dc.date.copyright | 2016-02-24 | |
| dc.date.issued | 2016 | |
| dc.date.submitted | 2016-01-14 | |
| dc.identifier.citation | Abdallah, B. Y., S. D. Horne, et al. (2014). 'Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer.' Syst Biol Reprod Med 60(1): 2-13.
Agarwal, R. and S. B. Kaye (2003). 'Ovarian cancer: strategies for overcoming resistance to chemotherapy.' Nat Rev Cancer 3(7): 502-516. Aghajanian, C., S. V. Blank, et al. (2012). 'OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.' J Clin Oncol 30(17): 2039-2045. Aghajanian, C., B. Goff, et al. (2015). 'Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.' Gynecol Oncol 139(1): 10-16. Akahira, J. I., H. Yoshikawa, et al. (2001). 'Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.' Gynecol Oncol 81(3): 398-403. Akhmedkhanov, A., P. Toniolo, et al. (2001). 'Aspirin and epithelial ovarian cancer.' Prev Med 33(6): 682-687. Al Rawahi, T., A. D. Lopes, et al. (2013). 'Surgical cytoreduction for recurrent epithelial ovarian cancer.' Cochrane Database Syst Rev 2: CD008765. Alama, A., F. Barbieri, et al. (1996). 'Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas.' Gynecol Oncol 62(1): 82-88. Aletti, G. D., S. C. Dowdy, et al. (2006). 'Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.' Obstet Gynecol 107(1): 77-85. Aletti, G. D., S. C. Dowdy, et al. (2007). 'Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system.' Gynecol Oncol 105(1): 84-89. Aletti, G. D., S. C. Dowdy, et al. (2007). 'Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.' Am J Obstet Gynecol 197(6): 676 e671-677. Allin, K. H., S. E. Bojesen, et al. (2012). 'Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population.' Br J Cancer 106(1): 199-205. Almeida, A., X. X. Zhu, et al. (1998). 'GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas.' Oncogene 16(23): 2997-3002. Aoki, D., N. Suzuki, et al. (2005). 'Establishment and characterization of the RMG-V cell line from human ovarian clear cell adenocarcinoma.' Hum Cell 18(3): 143-146. Ashworth, A. (2008). 'A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.' J Clin Oncol 26(22): 3785-3790. Bachmeier, B. E., C. M. Iancu, et al. (2005). 'Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach.' Expert Rev Anticancer Ther 5(1): 149-163. Banerjee, S. and S. Kaye (2011). 'PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.' Curr Oncol Rep 13(6): 442-449. Banerjee, S. and S. B. Kaye (2013). 'New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.' Clin Cancer Res 19(5): 961-968. Barnholtz-Sloan, J. S., A. G. Schwartz, et al. (2003). 'Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades.' Am J Obstet Gynecol 189(4): 1120-1127. Barton, C. A., N. F. Hacker, et al. (2008). 'DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment.' Gynecologic Oncology 109(1): 129-139. Baum, B., J. Settleman, et al. (2008). 'Transitions between epithelial and mesenchymal states in development and disease.' Semin Cell Dev Biol 19(3): 294-308. Bell, J., M. F. Brady, et al. (2006). 'Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.' Gynecol Oncol 102(3): 432-439. Beral, V., R. Doll, et al. (2008). 'Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.' Lancet 371(9609): 303-314. Bernardi, D., A. Padoan, et al. (2012). 'Serum YKL-40 following resection for cerebral glioblastoma.' J Neurooncol 107(2): 299-305. Berois, N., C. H. Gattolliat, et al. (2013). 'GALNT9 gene expression is a prognostic marker in neuroblastoma patients.' Clin Chem 59(1): 225-233. Bertelsen, K., A. Jakobsen, et al. (1993). 'A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).' Gynecol Oncol 49(1): 30-36. Berx, G. and F. van Roy (2009). 'Involvement of members of the cadherin superfamily in cancer.' Cold Spring Harb Perspect Biol 1(6): a003129. Bonnans, C., J. Chou, et al. (2014). 'Remodelling the extracellular matrix in development and disease.' Nat Rev Mol Cell Biol 15(12): 786-801. Bookman, M. A., H. Malmstrom, et al. (1998). 'Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.' J Clin Oncol 16(10): 3345-3352. Bordow, S. B., M. D. Norris, et al. (1998). 'Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.' J Clin Oncol 16(10): 3286-3294. Borley, J. and R. Brown (2015). 'Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.' Ann Med: 1-11. Bourne, T. H., S. Campbell, et al. (1993). 'Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging.' BMJ 306(6884): 1025-1029. Bray, F., A. H. Loos, et al. (2005). 'Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000.' Int J Cancer 113(6): 977-990. Brinton, L. A., G. Gridley, et al. (1997). 'Cancer risk after a hospital discharge diagnosis of endometriosis.' Am J Obstet Gynecol 176(3): 572-579. Brinton, L. A., L. C. Sakoda, et al. (2005). 'Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors.' Cancer Epidemiol Biomarkers Prev 14(12): 2929-2935. Bristow, R. E. and D. S. Chi (2006). 'Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.' Gynecol Oncol 103(3): 1070-1076. Bristow, R. E., E. L. Eisenhauer, et al. (2007). 'Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction.' Gynecol Oncol 104(2): 480-490. Bristow, R. E., F. J. Montz, et al. (1999). 'Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.' Gynecol Oncol 72(3): 278-287. Bristow, R. E., I. Puri, et al. (2009). 'Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.' Gynecol Oncol 112(1): 265-274. Bristow, R. E., R. S. Tomacruz, et al. (2002). 'Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.' J Clin Oncol 20(5): 1248-1259. Burger, R. A., M. F. Brady, et al. (2011). 'Incorporation of bevacizumab in the primary treatment of ovarian cancer.' N Engl J Med 365(26): 2473-2483. Cabanes, A., E. Vidal, et al. (2009). 'Age-specific breast, uterine and ovarian cancer mortality trends in Spain: changes from 1980 to 2006.' Cancer Epidemiol 33(3-4): 169-175. Caiola, E., M. Broggini, et al. (2014). 'Genetic markers for prediction of treatment outcomes in ovarian cancer.' Pharmacogenomics J 14(5): 401-410. Campos, S. M. and S. Ghosh (2010). 'A current review of targeted therapeutics for ovarian cancer.' J Oncol 2010: 149362. Carey, M. S., R. Agarwal, et al. (2010). 'Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy.' Clin Cancer Res 16(10): 2852-2860. Carlson, K. J., S. J. Skates, et al. (1994). 'Screening for ovarian cancer.' Ann Intern Med 121(2): 124-132. Casagrande, J. T., E. W. Louie, et al. (1979). ''Incessant ovulation' and ovarian cancer.' Lancet 2(8135): 170-173. Cass, I., R. L. Baldwin, et al. (2003). 'Improved survival in women with BRCA-associated ovarian carcinoma.' Cancer 97(9): 2187-2195. Celik, C., R. Abali, et al. (2012). 'Elevated circulating levels of YKL-40 are a marker of abnormal glucose tolerance in women with polycystic ovary syndrome.' Clin Endocrinol (Oxf) 77(6): 893-897. Chan, J. K., M. K. Cheung, et al. (2006). 'Patterns and progress in ovarian cancer over 14 years.' Obstet Gynecol 108(3 Pt 1): 521-528. Chan, J. K., V. Loizzi, et al. (2003). 'Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?' Obstet Gynecol 102(1): 156-161. Chan, J. K., A. E. Sherman, et al. (2011). 'Influence of gynecologic oncologists on the survival of patients with endometrial cancer.' J Clin Oncol 29(7): 832-838. Chan, J. K., C. Tian, et al. (2010). 'The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.' Gynecol Oncol 116(3): 301-306. Chan, J. K., C. Tian, et al. (2008). 'Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.' Cancer 112(10): 2202-2210. Chan, J. K., R. Urban, et al. (2006). 'Ovarian cancer in younger vs older women: a population-based analysis.' Br J Cancer 95(10): 1314-1320. Chen, C. C., J. Pekow, et al. (2011). 'Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia.' Am J Pathol 179(3): 1494-1503. Chen, C. Y., T. Y. Wen, et al. (2007). 'Determining estrogenic steroids in Taipei waters and removal in drinking water treatment using high-flow solid-phase extraction and liquid chromatography/tandem mass spectrometry.' Sci Total Environ 378(3): 352-365. Chen, D., J. Wang, et al. (2013). 'Effect of down-regulated transcriptional repressor ZEB1 on the epithelial-mesenchymal transition of ovarian cancer cells.' Int J Gynecol Cancer 23(8): 1357-1366. Chen, M. L., J. S. Chen, et al. (2008). 'The internal exposure of Taiwanese to phthalate--an evidence of intensive use of plastic materials.' Environ Int 34(1): 79-85. Chi, D. S., E. L. Eisenhauer, et al. (2006). 'What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?' Gynecol Oncol 103(2): 559-564. Chi, D. S., C. C. Franklin, et al. (2004). 'Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.' Gynecol Oncol 94(3): 650-654. Chiang, C. J., Y. C. Chen, et al. (2010). 'Cancer trends in Taiwan.' Jpn J Clin Oncol 40(10): 897-904. Chiang, Y. C., C. A. Chen, et al. (2013). 'Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan.' J Gynecol Oncol 24(4): 342-351. Chiang, Y. C., W. F. Cheng, et al. (2015). 'Establishment of a New Ovarian Cancer Cell Line CA5171.' Reprod Sci 22(6): 725-734. Chiang, Y. C., H. W. Lin, et al. (2015). 'Overexpression of CHI3L1 Is Associated with Chemoresistance and Poor Outcome of Epithelial Ovarian Carcinoma.' Oncotarget. Chornokur, G., E. K. Amankwah, et al. (2013). 'Global ovarian cancer health disparities.' Gynecol Oncol 129(1): 258-264. Choudhuri, S., C. Sharma, et al. (2014). 'A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer.' Mol Cell Biochem 386(1-2): 259-269. Chow, L. P. and N. K. Nair (1980). 'Oral contraceptive use and diseases of the circulatory system in Taiwan: an analysis of mortality statistics.' Int J Gynaecol Obstet 18(6): 420-432. Chu, C. S. and S. C. Rubin (2006). 'Screening for ovarian cancer in the general population.' Best Pract Res Clin Obstet Gynaecol 20(2): 307-320. Chudecka-Glaz, A., B. Gorski, et al. (2009). 'Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation--comparison to CA 125 antigen.' Eur J Gynaecol Oncol 30(6): 668-671. Chudecka-Glaz, A. M., A. A. Cymbaluk-Ploska, et al. (2014). 'Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.' J Ovarian Res 7: 62. Clarke-Pearson, D. L. (2009). 'Clinical practice. Screening for ovarian cancer.' N Engl J Med 361(2): 170-177. Cliby, W., S. Dowdy, et al. (2004). 'Diaphragm resection for ovarian cancer: technique and short-term complications.' Gynecol Oncol 94(3): 655-660. Cohen, C. J. and T. S. Jennings (1994). 'Screening for ovarian cancer: the role of noninvasive imaging techniques.' Am J Obstet Gynecol 170(4): 1088-1094. Coleman, R. L., B. J. Monk, et al. (2013). 'Latest research and treatment of advanced-stage epithelial ovarian cancer.' Nat Rev Clin Oncol 10(4): 211-224. conference., N. c. (1995). ' Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer.' JAMA 273(6): 491-497. Connolly, E. C., J. Freimuth, et al. (2012). 'Complexities of TGF-beta targeted cancer therapy.' Int J Biol Sci 8(7): 964-978. Corradi, M., M. Goldoni, et al. (2013). 'YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.' Anticancer Res 33(12): 5517-5524. Creasman, W. T. and P. J. DiSaia (1991). 'Screening in ovarian cancer.' Am J Obstet Gynecol 165(1): 7-10. Curtin, J. P., R. Malik, et al. (1997). 'Stage IV ovarian cancer: impact of surgical debulking.' Gynecol Oncol 64(1): 9-12. Danforth, K. N., S. S. Tworoger, et al. (2007). 'Breastfeeding and risk of ovarian cancer in two prospective cohorts.' Cancer Causes Control 18(5): 517-523. Dasari, S. and P. B. Tchounwou (2014). 'Cisplatin in cancer therapy: molecular mechanisms of action.' Eur J Pharmacol 740: 364-378. Davidowitz, R. A., L. M. Selfors, et al. (2014). 'Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.' J Clin Invest 124(6): 2611-2625. Davis, A., A. V. Tinker, et al. (2014). ''Platinum resistant' ovarian cancer: what is it, who to treat and how to measure benefit?' Gynecol Oncol 133(3): 624-631. Dehn, H., E. V. Hogdall, et al. (2003). 'Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.' Acta Obstet Gynecol Scand 82(3): 287-293. Deng, C. X. and F. Scott (2000). 'Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation.' Oncogene 19(8): 1059-1064. DePriest, P. D., H. H. Gallion, et al. (1997). 'Transvaginal sonography as a screening method for the detection of early ovarian cancer.' Gynecol Oncol 65(3): 408-414. Development, T. C. a. S. H. S. o. t. C. f. D. C. a. t. N. I. o. C. H. a. H. (1987). 'The reduction in risk of ovarian cancer associated with oral-contraceptive use. .' N Engl J Med 316(11): 650-655. Diefenbach, C. S., Z. Shah, et al. (2007). 'Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.' Gynecol Oncol 104(2): 435-442. Dowdy, S. C., R. T. Loewen, et al. (2008). 'Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma.' Gynecol Oncol 109(2): 303-307. Droegemueller, W. (1994). 'Screening for ovarian carcinoma: hopeful and wishful thinking.' Am J Obstet Gynecol 170(4): 1095-1098. du Bois, A., H. J. Luck, et al. (2003). 'A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.' J Natl Cancer Inst 95(17): 1320-1329. Duffy, M. J., P. M. McGowan, et al. (2008). 'Cancer invasion and metastasis: changing views.' J Pathol 214(3): 283-293. Dupont, J., M. K. Tanwar, et al. (2004). 'Early detection and prognosis of ovarian cancer using serum YKL-40.' J Clin Oncol 22(16): 3330-3339. Ebelt, N. D., M. A. Cantrell, et al. (2013). 'c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade.' Genes Cancer 4(9-10): 378-387. Eckstein, N. (2011). 'Platinum resistance in breast and ovarian cancer cell lines.' J Exp Clin Cancer Res 30: 91. Egeblad, M. and Z. Werb (2002). 'New functions for the matrix metalloproteinases in cancer progression.' Nat Rev Cancer 2(3): 161-174. Egger, G., G. Liang, et al. (2004). 'Epigenetics in human disease and prospects for epigenetic therapy.' Nature 429(6990): 457-463. Ehrlich, C. E., L. Einhorn, et al. (1983). 'Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cytoxan--the Indiana University experience.' Clin Obstet Gynaecol 10(2): 325-335. Eisenhauer, E. L., N. R. Abu-Rustum, et al. (2008). 'The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.' Gynecol Oncol 108(2): 276-281. Eisenhauer, E. L., N. R. Abu-Rustum, et al. (2006). 'The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.' Gynecol Oncol 103(3): 1083-1090. Eisenhauer, E. L., R. Salani, et al. (2012). Chapter 11 - Epithelial Ovarian Cancer. Clinical Gynecologic Oncology (Eighth Edition). P. J. D. S. T. Creasman. Philadelphia, Mosby: 285-328.e212. Eisenkop, S. M., R. L. Friedman, et al. (1998). 'Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.' Gynecol Oncol 69(2): 103-108. Elattar, A., A. Bryant, et al. (2011). 'Optimal primary surgical treatment for advanced epithelial ovarian cancer.' Cochrane Database Syst Rev(8): CD007565. Elzek, M. A. and K. D. Rodland (2015). 'Proteomics of ovarian cancer: functional insights and clinical applications.' Cancer Metastasis Rev 34(1): 83-96. Erickson, B. K., M. G. Conner, et al. (2013). 'The role of the fallopian tube in the origin of ovarian cancer.' Am J Obstet Gynecol 209(5): 409-414. Esteller, M. (2008). 'Epigenetics in cancer.' N Engl J Med 358(11): 1148-1159. Fader, A. N. and P. G. Rose (2007). 'Role of surgery in ovarian carcinoma.' J Clin Oncol 25(20): 2873-2883. Faibish, M., R. Francescone, et al. (2011). 'A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers.' Mol Cancer Ther 10(5): 742-751. Fan, F., S. Samuel, et al. (2012). 'Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells.' Cancer Med 1(1): 5-16. Fang, G. C., Y. S. Wu, et al. (2004). 'Polycyclic aromatic hydrocarbons in the ambient air of suburban and industrial regions of central Taiwan.' Chemosphere 54(4): 443-452. Feinberg, A. P. (2007). 'Phenotypic plasticity and the epigenetics of human disease.' Nature 447(7143): 433-440. Feinberg, A. P., R. Ohlsson, et al. (2006). 'The epigenetic progenitor origin of human cancer.' Nat Rev Genet 7(1): 21-33. Finkler, N. J., B. Benacerraf, et al. (1988). 'Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses.' Obstet Gynecol 72(4): 659-664. Fojo, T. and M. Menefee (2007). 'Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.' Ann Oncol 18 Suppl 5: v3-8. Folgueras, A. R., A. M. Pendas, et al. (2004). 'Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.' Int J Dev Biol 48(5-6): 411-424. Fong, P. C., T. A. Yap, et al. (2010). 'Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.' J Clin Oncol 28(15): 2512-2519. Francescone, R., N. Ngernyuang, et al. (2014). 'Tumor-derived mural-like cells coordinate with endothelial cells: role of YKL-40 in mural cell-mediated angiogenesis.' Oncogene 33(16): 2110-2122. Francescone, R. A., S. Scully, et al. (2011). 'Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma.' J Biol Chem 286(17): 15332-15343. Frank, T. S., S. A. Manley, et al. (1998). 'Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.' J Clin Oncol 16(7): 2417-2425. Fuh, K. C., A. A. Secord, et al. (2015). 'Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.' Gynecol Oncol. Galaal, K., R. Naik, et al. (2010). 'Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer.' Cochrane Database Syst Rev(6): CD007822. Galletti, E., M. Magnani, et al. (2007). 'Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes.' ChemMedChem 2(7): 920-942. Galluzzi, L., L. Senovilla, et al. (2012). 'Molecular mechanisms of cisplatin resistance.' Oncogene 31(15): 1869-1883. Galluzzi, L., I. Vitale, et al. (2014). 'Systems biology of cisplatin resistance: past, present and future.' Cell Death Dis 5: e1257. Gates, M. A., B. A. Rosner, et al. (2010). 'Risk factors for epithelial ovarian cancer by histologic subtype.' Am J Epidemiol 171(1): 45-53. Gatta, G., R. Capocaccia, et al. (2003). 'Cancer survival in European adolescents and young adults.' Eur J Cancer 39(18): 2600-2610. Gaver, R. C., N. Colombo, et al. (1988). 'The disposition of carboplatin in ovarian cancer patients.' Cancer Chemother Pharmacol 22(3): 263-270. Giordano, A., A. Fucito, et al. (2007). 'Carcinogenesis and environment: the cancer stem cell hypothesis and implications for the development of novel therapeutics and diagnostics.' Front Biosci 12: 3475-3482. Giroux, V., J. L. Iovanna, et al. (2009). 'Combined inhibition of PAK7, MAP3K7 and CK2alpha kinases inhibits the growth of MiaPaCa2 pancreatic cancer cell xenografts.' Cancer Gene Ther 16(9): 731-740. Goff, B. A., L. S. Mandel, et al. (2004). 'Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.' JAMA 291(22): 2705-2712. Gong, W., Z. An, et al. (2009). 'P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration.' Int J Cancer 125(3): 548-555. Gonzalez-Diego, P., G. Lopez-Abente, et al. (2000). 'Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death.' Eur J Cancer 36(14): 1816-1824. Gordon, A. N., M. Tonda, et al. (2004). 'Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.' Gynecol Oncol 95(1): 1-8. Grande, M., A. Franzen, et al. (2002). 'Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes.' J Cell Sci 115(Pt 22): 4227-4236. Greaves, M. (2015). 'Evolutionary Determinants of Cancer.' Cancer Discov. Greer, I. A. (2015). 'Pregnancy Complicated by Venous Thrombosis.' New England Journal of Medicine 373(6): 540-547. Greimel, E., G. B. Kristensen, et al. (2013). 'Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.' Gynecol Oncol 131(2): 437-444. Greimel, E. R., V. Bjelic-Radisic, et al. (2006). 'Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.' J Clin Oncol 24(4): 579-586. Grendys, E. C., Jr., J. V. Fiorica, et al. (2014). 'Overview of a chemoresponse assay in ovarian cancer.' Clin Transl Oncol 16(9): 761-769. Gronlund, B., E. V. Hogdall, et al. (2006). 'Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).' Int J Biol Markers 21(3): 141-148. Gross, T. P. and J. J. Schlesselman (1994). 'The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer.' Obstet Gynecol 83(3): 419-424. Group, I. C. O. N. (2002). 'Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.' Lancet 360(9332): 505-515. Grover, S., M. A. Quinn, et al. (1995). 'Screening for ovarian cancer using serum CA125 and vaginal examination: report on 2550 females.' Int J Gynecol Cancer 5(4): 291-295. Gu, J., K. Li, et al. (2013). 'A role for p21-activated kinase 7 in the development of gastric cancer.' FEBS J 280(1): 46-55. Gui, T. and K. Shen (2012). 'The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.' Cancer Epidemiol 36(5): 490-496. Guidozzi, F. and J. H. Ball (1994). 'Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer.' Gynecol Oncol 53(3): 326-330. Gurung, A., T. Hung, et al. (2013). 'Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.' Histopathology 62(1): 59-70. Hainsworth, J. D., H. W. Jones, 3rd, et al. (1990). 'The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).' Am J Clin Oncol 13(5): 410-415. Hamilton, T. C., R. C. Young, et al. (1983). 'Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.' Cancer Res 43(11): 5379-5389. Han, E. S., P. Lin, et al. (2009). 'Current status on biologic therapies in the treatment of epithelial ovarian cancer.' Curr Treat Options Oncol 10(1-2): 54-66. Hankinson, S. E., G. A. Colditz, et al. (1992). 'A quantitative assessment of oral contraceptive use and risk of ovarian cancer.' Obstet Gynecol 80(4): 708-714. Hankinson, S. E., D. J. Hunter, et al. (1993). 'Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study.' JAMA 270(23): 2813-2818. Harano, K., F. Terauchi, et al. (2014). 'Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016).' Ann Oncol 25(1): 251-257. Hart, W. R. (2005). 'Mucinous tumors of the ovary: a review.' Int J Gynecol Pathol 24(1): 4-25. Harter, P., A. du Bois, et al. (2006). 'Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.' Ann Surg Oncol 13(12): 1702-1710. Harutyunyan, M., J. P. Gotze, et al. (2013). 'Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.' Immunobiology 218(7): 945-951. Haslehurst, A. M., M. Koti, et al. (2012). 'EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.' BMC Cancer 12: 91. Hay, E. D. (1995). 'An overview of epithelio-mesenchymal transformation.' Acta Anat (Basel) 154(1): 8-20. Heintz, A. P., N. F. Hacker, et al. (1985). 'Epidemiology and etiology of ovarian cancer: a review.' Obstet Gynecol 66(1): 127-135. Henderson, B. E., R. K. Ross, et al. (1993). 'Hormonal chemoprevention of cancer in women.' Science 259(5095): 633-638. Hendrickson, M. R. and T. A. Longacre (1993). 'Classification of surface epithelial neoplasms of the ovary.' Pathology (Phila) 1(2): 189-254. Herman, J. G. and S. B. Baylin (2003). 'Gene silencing in cancer in association with promoter hypermethylation.' N Engl J Med 349(21): 2042-2054. Hiley, C., E. C. de Bruin, et al. (2014). 'Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine.' Genome Biol 15(8): 453. Hirabayashi, Y. and T. Marugame (2009). 'Comparison of time trends in ovary cancer mortality (1990-2006) in the world, from the WHO Mortality Database.' Jpn J Clin Oncol 39(12): 860-861. Hirte, H. W., J. S. Kaiser, et al. (1994). 'Establishment and characterization of four human epithelial ovarian carcinoma cell lines.' Cancer 74(3): 900-906. Hoffman, M. S., D. Griffin, et al. (2005). 'Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management.' Am J Obstet Gynecol 193(2): 582-586; discussion 586-588. Hogdall, E. V., J. S. Johansen, et al. (2003). 'High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.' Oncol Rep 10(5): 1535-1538. Hogdall, E. V., M. Ringsholt, et al. (2009). 'YKL-40 tissue expression and plasma levels in patients with ovarian cancer.' BMC Cancer 9: 8. Hoskins, W. J. (1989). 'The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer.' Baillieres Clin Obstet Gynaecol 3(1): 59-71. Hoskins, W. J., B. N. Bundy, et al. (1992). 'The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study.' Gynecol Oncol 47(2): 159-166. Hoskins, W. J., W. P. McGuire, et al. (1994). 'The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.' Am J Obstet Gynecol 170(4): 974-979; discussion 979-980. Hreshchyshyn, M. M., R. C. Park, et al. (1980). 'The role of adjuvant therapy in Stage I ovarian cancer.' Am J Obstet Gynecol 138(2): 139-145. Hua, H., M. Li, et al. (2011). 'Matrix metalloproteinases in tumorigenesis: an evolving paradigm.' Cell Mol Life Sci 68(23): 3853-3868. Huang, R. Y., V. Y. Chung, et al. (2012). 'Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer.' Curr Drug Targets 13(13): 1649-1653. Huang, Y. W., C. T. Kuo, et al. (2011). 'An overview of epigenetics and chemoprevention.' FEBS Lett 585(13): 2129-2136. Hugo, H., M. L. Ackland, et al. (2007). 'Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression.' J Cell Physiol 213(2): 374-383. Hunn, J. and G. C. Rodriguez (2012). 'Ovarian cancer: etiology, risk factors, and epidemiology.' Clin Obstet Gynecol 55(1): 3-23. Hurt, E. M., J. N. Saykally, et al. (2008). 'Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights.' Mol Cell Biochem 318(1-2): 89-99. International Agency for Research on Cancer, W. H. O. 'Cancer Incidence in Five Continents Annual Dataset.' http://ci5.iarc.fr/CI5plus/ci5plus.htm. Ioka, A., H. Tsukuma, et al. (2003). 'Ovarian cancer incidence and survival by histologic type in Osaka, Japan.' Cancer Sci 94(3): 292-296. Iwatsuki, M., K. Mimori, et al. (2010). 'Epithelial-mesenchymal transition in cancer development and its clinical significance.' Cance | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51592 | - |
| dc.description.abstract | 上皮性卵巢癌的發生率逐年升高，且其死亡率在婦女的惡性腫瘤中名列第一，在婦癌的領域中逐漸成為一個愈來愈重要的疾病，早期的上皮性卵巢癌往往沒有明確的症狀，大部分患者都已經達到晚期。上皮性卵巢癌的標準治療方式為腫瘤減積手術及輔助性化學治療通常治療後的初期反應在所有上皮性卵巢癌患者可達80%，在晚期患者可達40-60%，可是大部份患者於兩年內會復發，其中化療藥物的抗藥性在腫瘤的復發與惡化方面扮演了重要的角色，若能找出兼具預測臨床病程及代表腫瘤生物特性的因子，對於臨床診斷和治療將會很有助益。在第一個研究中，利用臺灣癌症登記系統全國資料庫的卵巢癌資料，來進行三十年來上皮性卵巢癌的發生率和預後的流行病學分析。研究發現這期間內漿液性腺癌、子宮內膜樣腺癌和明亮細胞癌的發生率增加，且最普遍的診斷年齡從60歲逐漸改變為50歲。在存活分析方面，黏液性腺癌、子宮內膜樣腺癌或明亮細胞癌患者的長期存活率比漿液性腺癌患者好(log rank test，p < 0.0001)；相反地，未分化癌或癌肉瘤患者的存活率比漿液性腺癌的患者差(log rank test，p < 0.0001)。以西元1991至1995年期間為基準，死亡的風險自西元1996至1999年期間逐漸減低(風險比：0.90，95%信賴區間：0.81-1.01，p = 0.054)，西元2000年以後更是明顯下降(風險比：0.74，95%信賴區間：0.67-0.82，p < 0.0001)。在第二個研究中，建立一個新的上皮性卵巢癌細胞株 - CA5171，它源自未接受化療的上皮性卵巢癌患者。CA5171細胞表現出上皮細胞的形態特徵，倍增時間約為24小時，CA5171有PIK3CA、PTEN和TP53基因的突變，單核苷酸多態性陣列分析顯示沒有同合性基因缺失，但有基因擴增的位點在染色體1、2、5、9、10、12、15、16、20和X。細胞毒性藥物與老鼠實驗顯示CA5171細胞對紫杉醇與阿黴素敏感，對順鉑有抗藥性。細胞所表現上皮間質轉化的特性可能是侵襲和遷移能力的原因，這些特性讓CA5171細胞株成為將來上皮性卵巢癌研究的有利工具。在第三個研究中，檢視上皮性卵巢癌患者組織CHI3L1基因表現與臨床預後的關聯性，研究發現漿液性腺癌患者、晚期患者或化療抗藥性患者有顯著較高的CHI3L1基因表現。高CHI3L1表現患者無病存活期(p<0.001)與整體存活期(p<0.001)顯著較短，高CHI3L1表現是疾病復發(風險比：2.91，95%信賴區間：1.89−4.48，p<0.001)和疾病死亡(風險比：4.03，95%信賴區間：2.37−6.87，p<0.001)的重要風險因子。細胞株研究顯示，CHI3L1基因可藉由提高Mcl-1的表現來抑制紫杉醇引起的卵巢癌細胞凋亡。由此可見CHI3L1基因可做為上皮性卵巢癌患者有潛力的預後指標。總結而言，三十年癌症登記資料庫的分析提供了台灣地區卵巢癌長期流行病學方面的資訊；所建立的CA5171細胞株是上皮性卵巢癌研究的有利工具；CHI3L1基因可做為上皮性卵巢癌患者有潛力的預後指標。 | zh_TW |
| dc.description.abstract | Epithelial ovarian carcinoma has the highest mortality rate among gynecologic malignancies and is an important disease in the field. Early diagnosis is difficult due to the lack of obvious initial symptoms, therefore ovarian cancer patients are usually diagnosed at advanced stage. Current treatments include debulking surgery and adjuvant chemotherapy with the regimen of platinum and paclitaxel which have a response rate of 80% for all patients and 40-60% for advanced-staged patients, but they usually relapse after initial response and ultimately die of recurrence. Chemo-resistance is an obstacle in the managements of epithelial ovarian cancer. A clinical prognostic factor reflecting the possible mechanisms and biological characteristics of oncogenesis or chemo-resistance may be helpful in the development of new therapeutic strategies. In the first study, we conducted the nationwide database analysis through Taiwan cancer registry system from 1979 to 2008 to evaluate the pattern, incidence and prognosis of epithelial ovarian carcinomas in the last three decades. The age-specific incidence rates increased especially in serous, endometrioid and clear cell carcinoma, and the age of diagnosis decreased from sixty to fifty years old in the three decades. Patients with mucinous, endometrioid, or clear cell carcinoma had better long-term survival than patients with serous carcinoma (log rank test, p<0.001). Patients with undifferentiated carcinoma or carcinosarcoma had poorer survival than those with serous carcinoma (log rank test, p<0.001). The mortality risk decreased from the period of 1996-1999 (hazard ratio [HR]: 0.90, p=0.054) to the period after 2000 (HR: 0.74, p<0.001) as compared with that from the period of 1991-1995. In the second study, we reported a new cell line, CA5171, derived from a chemotherapy-naive, epithelial ovarian carcinoma patient. The CA5171 cells presented with cobblestone morphology and a doubling time of 24 hours. Gene mutation analysis showed that the cells belonged to the type II ovarian cancer pathway with mutations of PIK3CA, PTEN and TP53. Single-nucleotide polymorphism array analysis showed no homozygous gene deletion; however, several loci of gene copy number gains were noted in chromosome 1, 2, 5, 9, 10, 12, 15, 16, 20 and X. The in vitro and in vivo experiments showed that the cells were sensitive to paclitaxel and doxorubicin, but resistant to cisplatin. The cells also presented epithelial–mesenchymal transition properties that may have been related to their invasion and migration potential. The CA5171 cells show the potential as a new cell line for studies on epithelial ovarian carcinoma. In the third study, the association of CHI3L1 expression and clinical outcomes of epithelial ovarian carcinoma patients were investigated. The expression of CHI3L1 was also higher in patients with a serous histological type, advanced stage, and chemo-resistance. Patients with high CHI3L1 expression had a shorter progression free survival (log rank test, p < 0.001) and overall survival (log rank test, p < 0.001). Patients with high CHI3L1 expression also had a high risk of recurrence (HR: 2.91, 95% CI: 1.89−4.48, p < 0.001) and death (HR: 4.03, 95% CI: 2.37−6.87, p < 0.001). In vitro studies showed that CHI3L1 up-regulated the expression of anti-apoptotic Mcl-1 protein and hampered paclitaxel-induced apoptosis of ovarian cancer cells. These results suggest that CHI3L1 shows potential as a prognostic biomarker for epithelial ovarian carcinoma. In summary, the nationwide database analysis provided the long-term epidemiological information of epithelial ovarian cancer in Taiwan. The CA5171 cell line had the potential as a new tool for studies on epithelial ovarian carcinoma. The CHI3L1 expression of ovarian cancer tissue was a potential marker for epithelial ovarian cancer patients. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T13:40:17Z (GMT). No. of bitstreams: 1 ntu-105-Q96421009-1.pdf: 5561944 bytes, checksum: a2c37dd01717f8857f5ead90b21279ab (MD5) Previous issue date: 2016 | en |
| dc.description.tableofcontents | 第一章：緒論(1)
第二章：研究方法與材料(28) 第三章：結果(41) 第四章：討論(53) 第五章：展望(74) 論文英文簡述(84) 參考文獻(109) 圖(138) 表(151) 附錄：博士班修業期間所發表之相關論文清冊(160) | |
| dc.language.iso | zh-TW | |
| dc.subject | YKL-40 | zh_TW |
| dc.subject | 上皮性卵巢癌 | zh_TW |
| dc.subject | 流行病學 | zh_TW |
| dc.subject | 卵巢癌細胞株 | zh_TW |
| dc.subject | CA5171 | zh_TW |
| dc.subject | CHI3L1 | zh_TW |
| dc.subject | epidemiology | en |
| dc.subject | CHI3L1 | en |
| dc.subject | CA5171 | en |
| dc.subject | ovarian cancer cell line | en |
| dc.subject | epithelial ovarian cancer | en |
| dc.subject | YKL-40 | en |
| dc.title | 上皮性卵巢癌的流行病學與預後指標之研究 | zh_TW |
| dc.title | The Studies of Epidemiology and Prognostic Markers in Epithelial Ovarian Carcinoma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 104-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 周振陽,成佳憲,何志明,陳沛隆 | |
| dc.subject.keyword | 上皮性卵巢癌,流行病學,卵巢癌細胞株,CA5171,CHI3L1,YKL-40, | zh_TW |
| dc.subject.keyword | epithelial ovarian cancer,epidemiology,ovarian cancer cell line,CA5171,CHI3L1,YKL-40, | en |
| dc.relation.page | 160 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2016-01-14 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-105-1.pdf 未授權公開取用 | 5.43 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。